Summary of the risk management plan for Vigamox (Moxifloxacin hydrochloride)

This is a summary of the risk management plan (RMP) for Vigamox. The RMP details important risks of Vigamox, how these risks can be minimized, and how more information will be obtained about Vigamox's risks and uncertainties (missing information).

Vigamox's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how Vigamox should be used.

This summary of the RMP for Vigamox should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR).

Important new concerns or changes to the current ones will be included in updates of Vigamox's RMP.

I. The medicine and what it is used for

Vigamox is authorized for topical treatment of purulent bacterial conjunctivitis, caused by moxifloxacin susceptible strains. It contains moxifloxacin hydrochloride as the active substance, and it is given as eye drop. It is available as 1 ml of solution contains 5.45 mg moxifloxacin hydrochloride equivalent to 5 mg moxifloxacin base.

II. Risks associated with the medicine and activities to minimize or further characterize the risks

Important risks of Vigamox, together with measures to minimize such risks and the proposed studies for learning more about Vigamox's risks, are outlined below.

Measures to minimize the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimize its risks.

Together, these measures constitute routine risk minimization measures.

II.A: List of important risks and missing information

Important risks of Vigamox are risks that need special risk management activities to further investigate or minimize the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Vigamox. Potential risks are concerns for which an association with the use of this

medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

Table 1 List of important risks and missing information

List of important risks and missing information	
Important identified risks	None
Important potential risks	None
Missing information	None

II.B: Summary of important risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C: Post-authorization development plan

II.C.1. Studies which are conditions of the marketing authorization

There are no studies which are conditions of the marketing authorization or specific obligation of Vigamox.

II.C.2. Other studies in post-authorization development plan

There are no studies required for Vigamox.